CLDF Title
Contact Us | Bookmark
About CLDF Centers of Educational Expertise  
Live CME Meetings Webcasts Slide Library Abstract Library Conference Highlights
Featured Programs
  Liver News - REUTERS   Congress Calendar   Physician Resources  
Screening, brief behavioral counseling can reduce unhealthy alcohol use
Routine monitoring unneeded for most patients on oral dermatophyte therapy
Novartis, Pfizer join forces on potentially lucrative fatty liver disease
HCV core antigen cost-saving alternative for diagnosing hepatitis C
"Compelling" evidence of link between aspirin use, lower hepatoma risk
View Complete News Library
View all Congresses
  Featured Abstracts          
Factors Associated with Histologic Response in Adult Patients with Nonalcoholic SteatohepatitisL
Burden of Illness and Economic Model for Patients with Non-Alcoholic Steatohepatitis (NASH) in the United States
Utility and variability of three non-invasive liver fibrosis imaging modalities to evaluate efficacy of GR-MD-02 in subjects with NASH and bridging fibrosis during a phase-2 randomized clinical trial
GS-0976 Reduces Hepatic Steatosis and Fibrosis Markers in Patients with Nonalcoholic Fatty Liver Disease
Hepatocellular carcinoma among US and non-US-born patients with chronic hepatitis B: Risk factors and age at diagnosis
Towards the elimination of hepatitis B and hepatocellular carcinoma
Perinatal Transmission of Hepatitis C Virus: Defining the Cascade of Care
Hepatitis C virus reinfection after successful treatment with direct-acting antiviral therapy in a large population-based cohort
'Hep C's like the common cold': understanding barriers along the HCV care continuum among young people who inject drugs
Safety and Efficacy of Ledipasvir-Sofosbuvir With or Without Ribavirin for Chronic Hepatitis Cin Children Ages 6-11
Meeting the Challenge: Hepatitis C Virus and HIV Care Experiences Among HIV Specialty Providers
Population level outcomes and cost-effectiveness of hepatitis C treatment pre- vs postkidney transplantation
A comprehensive assessment of patient reported symptom burden, medical comorbidities, and functional well being in patients initiating direct acting antiviral therapy for chronic hepatitis C: Results from a large US multi-center observational study
A Head CT is Unnecessary in the Initial Evaluation of A Cirrhotic Patient with Recurrent Hepatic Encephalopathy
Lack of Patient Compliance in Real-World Practice Negatively Affects Sustained Viral Response Rates to Direct Acting Agent Therapy for Hepatitis C
Evaluating HCV screening, linkage to care, and treatment across insurers
Successful Implementation of a Shared Medical Appointment Model for Hepatitis C Treatment at a Community Health Center
Using HIV Surveillance Data for Targeted, Community-based Hepatitis C Virus Testing among Baby Boomers in Washington, D.C
Eliminating hepatitis C: The importance of frequent testing of people who inject drugs in high-prevalence settings
The Role of Angiogenesis in Hepatocellular Carcinoma
Association Between Aspirin Use and Risk of Hepatocellular Carcinoma
Burden of Liver Diseases in the World
Targeted and Immune-based Therapies for Hepatocellular Carcinoma
Outcomes of sequential treatment with sorafenib followed by regorafenib for HCC: Additional analyses from the phase III RESORCE trial
Regorafenib in hepatocellular carcinoma: latest evidence and clinical implications
Clinical outcomes with long-term sorafenib treatment of patients with hepatocellular carcinoma: a multicenter real-life study
Advanced Hepatocellular Carcinoma Tumor Stage at Diagnosis in the 1945-1965 Birth Cohort Reflects Poor Use of Hepatocellular Carcinoma Screening
Application of the Doylestown algorithm for the early detection of hepatocellular carcinoma
Primary Care Provider Practice Patterns and Barriers to Hepatocellular Carcinoma Surveillance
Alpha-fetoprotein kinetics in patients with hepatocellular carcinoma receiving ramucirumab or placebo: an analysis of the phase 3 REACH study
Olfactory Function is Affected in Patients with Cirrhosis Depending on the Severity of Hepatic Encephalopathy
Current Management of Hepatic Encephalopathy
Evaluation of the cost-effectiveness of rifaximin-α for the management of patients with hepatic encephalopathy in the United Kingdom
Coil-Assisted Retrograde Transvenous Obliteration (CARTO): An Alternative Treatment Option for Refractory Hepatic Encephalopathy
Systematic Review of the Economic Burden of Overt Hepatic Encephalopathy and Pharmacoeconomic Impact of Rifaximin
Overview of Updated Practice Guidelines for Pediatric Nonalcoholic Fatty Liver Disease
Putting non-alcoholic fatty liver disease on the radar for primary care physicians: how well are we doing?
Real-world data reveal a diagnostic gap in non-alcoholic fatty liver disease
The Conundrum of Cryptogenic Cirrhosis: Adverse Outcomes without Treatment Options
Global Perspectives on Non-alcoholic Fatty Liver Disease and Non-alcoholic Steatohepatitis
          View All Abstracts  
Slide Library
Abstract Library
Slide Library
Abstract Library
Slide Library
Abstract Library
Slide Library
Abstract Library
Slide Library
Abstract Library
Slide Library
Abstract Library
Slide Library
About CLDF
Mission Statement
Board of Trustees
Board of Advisors
CLDF Sponsors & Supporters
Other Resources
Liver News Library
Journal Abstracts
Hep C Link to Care
Centers of
Educational Expertise
Substance Use Disorder
CLDF Follow Us
  The Chronic Liver Disease Foundation is a non-profit organization with content developed specifically for healthcare professionals.
© Copyright 2012-2018 Chronic Liver Disease Foundation. All rights reserved. This site is maintained as an educational resource for US healthcare providers only.
Use of this Web site is governed by the Chronic Liver Disease Foundation terms of use and privacy statement.